108 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Bernardi A, Ballestero P, Schenk M, Ferrario M, Gómez G, Rivero R, Avale E, Taravini I, Gershanik O, Guerrero S, Ferrario JE. Yerba mate (Ilex paraguariensis) favors survival and growth of dopaminergic neurons in culture. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30938849 DOI: 10.1002/mds.27667  0.76
2018 Lizarraga KJ, Thompson PD, Moore HP, Mizraji G, Gershanik OS, Singer C, Lang AE. Dancing Dorsal Quadrilaterals: A Novel Peripherally Induced Movement Disorder. Jama Neurology. PMID 30556833 DOI: 10.1001/jamaneurol.2018.3948  0.76
2018 Esteves S, Gleichgerrcht E, Torralva T, Chade A, Gómez Arévalo G, Gershanik O, Manes F, Roca M. Performance of Patients with Early Parkinson Disease on an Executive and Social Cognition Battery. Cognitive and Behavioral Neurology : Official Journal of the Society For Behavioral and Cognitive Neurology. 31: 142-150. PMID 30239464 DOI: 10.1097/WNN.0000000000000159  0.76
2018 Skorvanek M, Martinez-Martin P, Kovacs N, Zezula I, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Aviles-Olmos I, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Benchetrit E, ... ... Gershanik O, et al. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism & Related Disorders. PMID 29625875 DOI: 10.1016/j.parkreldis.2018.03.027  0.76
2018 Stefani A, Heidbreder A, Brandauer E, Guaita M, Neier LM, Mitterling T, Santamaria J, Iranzo A, Videnovic A, Trenkwalder C, Sixel-Döring F, Wenning GK, Chade A, Poewe W, Gershanik OS, et al. Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy. Sleep. 41. PMID 29554362 DOI: 10.1093/sleep/zsy053  0.76
2017 Sanchez Abraham M, Gomez Arevalo GJ, Garcia SS, Gershanik OS. A Functional Parkinsonian Tremor in a Pediatric Patient. Movement Disorders Clinical Practice. 4: 275-276. PMID 30838268 DOI: 10.1002/mdc3.12414  0.76
2017 Skorvanek M, Martinez-Martin P, Kovacs N, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Foltynie T, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Aviles-Olmos I, Benchetrit E, ... ... Gershanik O, et al. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. Movement Disorders Clinical Practice. 4: 536-544. PMID 30363418 DOI: 10.1002/mdc3.12476  0.76
2017 Sanchez Abraham M, Gomez Arevalo G, Garcia SS, Mizraji G, Chade A, Gershanik O. Decreased Palpebral Fissure in Patients with Parkinson's Disease. Movement Disorders Clinical Practice. 4: 58-61. PMID 30363399 DOI: 10.1002/mdc3.12346  0.76
2017 Gomez G, Saborido MD, Alejandra Bernardi M, Gershanik OS, Taravini IR, Ferrario JE. Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia. Neuroscience Letters. 666: 5-10. PMID 29241709 DOI: 10.1016/j.neulet.2017.12.024  0.76
2017 Sanz-Blasco S, Bordone MP, Damianich A, Gomez G, Bernardi MA, Isaja L, Taravini IR, Hanger DP, Avale ME, Gershanik OS, Ferrario JE. The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease. Molecular Neurobiology. PMID 28840468 DOI: 10.1007/s12035-017-0748-3  0.76
2015 Torralva T, Laffaye T, Báez S, Gleichgerrcht E, Bruno D, Chade A, Ibañez A, Manes F, Gershanik O, Roca M. Verbal Fluency as a Rapid Screening Test for Cognitive Impairment in Early Parkinson's Disease. The Journal of Neuropsychiatry and Clinical Neurosciences. appineuropsych140601. PMID 26067437 DOI: 10.1176/appi.neuropsych.14060139  1
2015 Taravini IR, Larramendy C, Gomez G, Saborido MD, Spaans F, Fresno C, González GA, Fernández E, Murer MG, Gershanik OS. Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease. Neuropharmacology. PMID 25963416 DOI: 10.1016/j.neuropharm.2015.04.018  0.76
2015 Baez S, Herrera E, Gershanik O, Garcia AM, Bocanegra Y, Kargieman L, Manes F, Ibanez A. Impairments in negative emotion recognition and empathy for pain in Huntington's disease families. Neuropsychologia. 68: 158-67. PMID 25582408 DOI: 10.1016/j.neuropsychologia.2015.01.012  1
2015 Gershanik OS. Improving L-dopa therapy: the development of enzyme inhibitors. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 103-13. PMID 25335824 DOI: 10.1002/mds.26050  1
2015 Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, et al. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 22: 37-43. PMID 23607783 DOI: 10.1111/ene.12165  1
2015 Abraham MS, Gershanik OS. Ataxia Medication-Induced Movement Disorders. 150-159. DOI: 10.1017/CBO9781107588738.015  1
2015 Taravini IR, Larramendy C, Gomez G, Saborido MD, Spaans F, Fresno C, González GA, Fernández E, Murer MG, Gershanik OS. Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease Neuropharmacology. DOI: 10.1016/j.neuropharm.2015.04.018  1
2014 Kargieman L, Herrera E, Baez S, García AM, Dottori M, Gelormini C, Manes F, Gershanik O, Ibáñez A. Motor-Language Coupling in Huntington's Disease Families. Frontiers in Aging Neuroscience. 6: 122. PMID 24971062 DOI: 10.3389/fnagi.2014.00122  1
2014 Scocco DH, Wagner JN, Racosta J, Chade A, Gershanik OS. Subjective visual vertical in Pisa syndrome. Parkinsonism & Related Disorders. 20: 878-83. PMID 24857768 DOI: 10.1016/j.parkreldis.2014.04.030  1
2014 Cardona JF, Kargieman L, Sinay V, Gershanik O, Gelormini C, Amoruso L, Roca M, Pineda D, Trujillo N, Michon M, García AM, Szenkman D, Bekinschtein T, Manes F, Ibáñez A. How embodied is action language? Neurological evidence from motor diseases. Cognition. 131: 311-22. PMID 24594627 DOI: 10.1016/j.cognition.2014.02.001  1
2014 Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, Alvarez-Sánchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martínez-Castrillo JC, Mendoza-Rodríguez A, Moore HP, Rodríguez-Violante M, Singer C, et al. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 21: 519-24. PMID 24447695 DOI: 10.1111/ene.12349  1
2014 Högl B, Agostino PV, Peralta MC, Gershanik O, Golombek DA. Alterations in time estimation in multiple system atrophy Basal Ganglia. 4: 95-99. DOI: 10.1016/j.baga.2014.06.004  1
2013 Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, et al. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism & Related Disorders. 19: 889-93. PMID 23791519 DOI: 10.1016/j.parkreldis.2013.05.017  1
2013 Cardona JF, Gershanik O, Gelormini-Lezama C, Houck AL, Cardona S, Kargieman L, Trujillo N, Arévalo A, Amoruso L, Manes F, Ibáñez A. Action-verb processing in Parkinson's disease: new pathways for motor-language coupling. Brain Structure & Function. 218: 1355-73. PMID 23412746 DOI: 10.1007/s00429-013-0510-1  1
2013 Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Journal of Neurology. 260: 228-36. PMID 22865238 DOI: 10.1007/s00415-012-6624-1  1
2013 Ibáñez A, Cardona JF, Dos Santos YV, Blenkmann A, Aravena P, Roca M, Hurtado E, Nerguizian M, Amoruso L, Gómez-Arévalo G, Chade A, Dubrovsky A, Gershanik O, Kochen S, Glenberg A, et al. Motor-language coupling: direct evidence from early Parkinson's disease and intracranial cortical recordings. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior. 49: 968-84. PMID 22482695 DOI: 10.1016/j.cortex.2012.02.014  1
2012 Roca M, Manes F, Chade A, Gleichgerrcht E, Gershanik O, Arévalo GG, Torralva T, Duncan J. The relationship between executive functions and fluid intelligence in Parkinson's disease. Psychological Medicine. 42: 2445-52. PMID 22440401 DOI: 10.1017/S0033291712000451  1
2012 Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 19: 1502-8. PMID 22221452 DOI: 10.1111/j.1468-1331.2011.03593.x  1
2012 Gershanik OS. Are we ready for a new definition of Parkinson's disease? Basal Ganglia. 2: 55-56. DOI: 10.1016/j.baga.2012.03.002  1
2011 Taravini IR, Chertoff M, Cafferata EG, Courty J, Murer MG, Pitossi FJ, Gershanik OS. Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats. Molecular Neurodegeneration. 6: 40. PMID 21649894 DOI: 10.1186/1750-1326-6-40  1
2011 Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-Moriyama L, Azulay JP, Gershanik OS, Bloem BR. Postural deformities in Parkinson's disease. The Lancet. Neurology. 10: 538-49. PMID 21514890 DOI: 10.1016/S1474-4422(11)70067-9  1
2011 Gershanik OS, Gómez Arévalo GJ. Typical and atypical neuroleptics. Handbook of Clinical Neurology. 100: 579-99. PMID 21496609 DOI: 10.1016/B978-0-444-52014-2.00042-2  1
2010 Gershanik OS. Clinical problems in late-stage Parkinson's disease. Journal of Neurology. 257: S288-91. PMID 21080191 DOI: 10.1007/s00415-010-5717-y  1
2010 Roca M, Torralva T, Gleichgerrcht E, Chade A, Arévalo GG, Gershanik O, Manes F. Impairments in social cognition in early medicated and unmedicated Parkinson disease. Cognitive and Behavioral Neurology : Official Journal of the Society For Behavioral and Cognitive Neurology. 23: 152-8. PMID 20829664 DOI: 10.1097/WNN.0b013e3181e078de  1
2009 Gershanik OS. Stiff-person syndrome. Parkinsonism & Related Disorders. 15: S130-4. PMID 20082974 DOI: 10.1016/S1353-8020(09)70799-0  1
2009 Gatto EM, Garretto NS, Etcheverry JL, Persi GG, Parisi VL, Gershanik O. Corticobasal degeneration presenting as complex regional pain syndrome. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 947-8. PMID 19224616 DOI: 10.1002/mds.22475  1
2009 Gershanik OS. Medical management of L-dopa motor complications Focus On Parkinson's Disease. 21: 4-9.  1
2008 Chade A, Roca M, Torralva T, Gleichgerrcht E, Fabbro N, Arévalo GG, Gershanik O, Manes F. Detecting cognitive impairment in patients with Parkinson's disease with a brief cognitive screening tool: the Addenbrooke's Cognitive Examination (ACE). Dementia & Neuropsychologia. 2: 197-200. PMID 29213570 DOI: 10.1590/S1980-57642009DN20300006  0.76
2008 Larramendy C, Taravini IR, Saborido MD, Ferrario JE, Murer MG, Gershanik OS. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism. Behavioural Brain Research. 194: 44-51. PMID 18638507 DOI: 10.1016/j.bbr.2008.06.021  1
2008 Gershanik OS. Other Drug-Induced Dyskinesias Therapeutics of Parkinson's Disease and Other Movement Disorders. 389-403. DOI: 10.1002/9780470713990.ch26  1
2007 Gershanik OS. Trauma and Parkinson's disease. Handbook of Clinical Neurology. 84: 487-99. PMID 18808966 DOI: 10.1016/S0072-9752(07)84057-7  1
2007 Roessner V, Becker A, Banaschewski T, Freeman RD, Rothenberger A. Developmental psychopathology of children and adolescents with Tourette syndrome--impact of ADHD. European Child & Adolescent Psychiatry. 16: 24-35. PMID 17665280 DOI: 10.1007/s00787-007-1004-6  1
2007 Freeman RD. Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome. European Child & Adolescent Psychiatry. 16: 15-23. PMID 17665279 DOI: 10.1007/s00787-007-1003-7  1
2007 Delfino M, Kalisch R, Czisch M, Larramendy C, Ricatti J, Taravini IR, Trenkwalder C, Murer MG, Auer DP, Gershanik OS. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 1911-21. PMID 17287822 DOI: 10.1038/sj.npp.1301329  1
2006 Arakaki T, Bauso D, Bueri J, Cammarota A, Cersosimo MG, Chade A, Closter G, Diaz S, Femminini R, Fernandez Pardal M, Barreto N, Gatto E, Gershanik O, Giannaula R, Gomez Arevalo GJ, et al. Surgical treatment guidelines for Parkinson's disease | Guia de tratamiento quirurgico de la enfermedad de Parkinson Revista Neurologica Argentina. 31: 123-128.  1
2006 Arakaki T, Bauso D, Bueri J, Cammarota A, Cersosimo MG, Chade A, Closter G, Diaz S, Femminini R, Fernandez Pardal M, Barreto N, Gatto E, Gershanik O, Giannaula R, Gomez Arevalo GJ, et al. Guidelines for the use of dopaminergic agonists | Guia para el uso de agonistas dopaminergicos Revista Neurologica Argentina. 31: 129-133.  1
2005 Taravini IR, Ferrario JE, Delbe J, Ginestet L, Debeir T, Courty J, Murer MG, Gershanik OS, Raisman-Vozari R. Immunodetection of heparin-binding growth associated molecule (pleiotrophin) in striatal interneurons. Brain Research. 1066: 196-200. PMID 16325783 DOI: 10.1016/j.brainres.2005.10.055  1
2004 Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 997-1005. PMID 15372588 DOI: 10.1002/mds.20243  1
2004 Ferrario JE, Taravini IR, Mourlevat S, Stefano A, Delfino MA, Raisman-Vozari R, Murer MG, Ruberg M, Gershanik O. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. Journal of Neurochemistry. 90: 1348-58. PMID 15341519 DOI: 10.1111/j.1471-4159.2004.02595.x  1
2004 Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Cns Drugs. 18: 733-46. PMID 15330687 DOI: 10.2165/00023210-200418110-00003  1
2004 Delfino MA, Stefano AV, Ferrario JE, Taravini IR, Murer MG, Gershanik OS. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behavioural Brain Research. 152: 297-306. PMID 15196797 DOI: 10.1016/j.bbr.2003.10.009  1
2003 Ferrario JE, Delfino MA, Stefano AV, Zbarsky V, Douhou A, Murer MG, Raisman-Vozari R, Gershanik OS. Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neuroscience Research. 47: 431-6. PMID 14630347 DOI: 10.1016/j.neures.2003.08.001  1
2003 Gershanik O, Emre M, Bernhard G, Sauer D. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 963-71. PMID 14499313 DOI: 10.1016/S0278-5846(03)00156-8  1
2003 Gershanik OS. Early onset parkinsonism. Frontiers in Bioscience : a Journal and Virtual Library. 8: s568-78. PMID 12700083  1
2002 Gershanik OS. [Dementia and cognitive impairment in Parkinson disease]. Vertex (Buenos Aires, Argentina). 13: 184-8. PMID 12404019  1
2002 Moyano B, Cecilia Peralta M, Figiacone S, Márquez M, Gershanik OS. Neuropsychiatric assessment in an argentine sample of patients with Tourette Syndrome | Evaluación neuropsiquiátrica en una muestra Argentina de pacientes con Síndrome de Tourette Prensa Medica Argentina. 89: 665-677.  1
2001 Högl B, Peralta C, Wetter TC, Gershanik O, Trenkwalder C. Effect of sleep deprivation on motor performance in patients with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 616-21. PMID 11481684 DOI: 10.1002/mds.1138  1
2001 Wetter TC, Trenkwalder C, Gershanik O, Högl B. Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances. Wiener Klinische Wochenschrift. 113: 249-53. PMID 11383385  1
2001 Ferrario J, Murer MG, Raisman-Vozari R, Gershanik O. Chronic levodopa for Parkinson's disease: Beyond toxicity Focus On Parkinson's Disease. 13: 32-36.  1
2000 Tseng KY, Roubert C, Do L, Rubinstein M, Kelly MA, Grandy DK, Low MJ, Gershanik OS, Murer MG, Giros B, Raisman-Vozari R. Selective increase of Nurr1 mRNA expression in mesencephalic dopaminergic neurons of D2 dopamine receptor-deficient mice. Brain Research. Molecular Brain Research. 80: 1-6. PMID 11039723 DOI: 10.1016/S0169-328X(00)00107-8  1
2000 Murer MG, Dziewczapolski G, Salin P, Vila M, Tseng KY, Ruberg M, Rubinstein M, Kelly MA, Grandy DK, Low MJ, Hirsch E, Raisman-Vozari R, Gershanik O. The indirect basal ganglia pathway in dopamine D(2) receptor-deficient mice. Neuroscience. 99: 643-50. PMID 10974427 DOI: 10.1016/S0306-4522(00)00223-2  1
2000 Högl B, Gershanik O. Sleep benefit in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 68: 798-9. PMID 10877630 DOI: 10.1136/jnnp.68.6.798  1
2000 Lera G, Scipioni O, Garcia S, Cammarota A, Fischbein G, Gershanik O. A combined pattern of movement disorders resulting from posterolateral thalamic lesions of a vascular nature: a syndrome with clinico-radiologic correlation. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 120-6. PMID 10634250  1
1999 Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 911-3. PMID 10584663 DOI: 10.1002/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO;2-H  1
1999 Menalled LB, Dziewczapolski G, Garcia MC, Rubinstein M, Gershanik OS. D3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion. Neuroreport. 10: 3131-6. PMID 10574548  1
1999 Murer MG, Raisman-Vozari R, Gershanik O. Levodopa in Parkinson's disease: neurotoxicity issue laid to rest? Drug Safety. 21: 339-52. PMID 10554050 DOI: 10.2165/00002018-199921050-00001  1
1999 Golbe LI, Di Iorio G, Lazzarini A, Vieregge P, Gershanik OS, Bonavita V, Duvoisin RC. The Contursi kindred, a large family with autosomal dominant Parkinson's disease: implications of clinical and molecular studies. Advances in Neurology. 80: 165-70. PMID 10410717  1
1999 Murer MG, Ferrario J, Delfino M, Dziewczapolski G, Gershanik OS, Raisman-Vozari R. Increased [125I]sulpiride binding in the subthalamic nucleus of rats with nigrostriatal lesions. Neuroreport. 10: 1501-5. PMID 10380970  1
1999 De Simone V, Sinay V, Serrano C, Kadar J, Viaggio B, Gershanik O, Taratuto A. Linfoma leptomeningeo primario: Un procedimiento invasivo para una terapeutica precoz Revista Neurologica Argentina. 24: 190.  1
1999 Serrano C, Sinay V, Kadar J, Desimone V, Gershanik O, Taratuto A. Fibrohistiocitoma maligno: Tumor primario inusual del SNC Revista Neurologica Argentina. 24: 190.  1
1999 De Simone V, Peralta C, Sinay V, Serrano C, Kadar J, Chade A, Gershanik O. La nocardiosis es otra causa de abscesos cerebrales en inmunocomprometidos con alta mortalidad Revista Neurologica Argentina. 24: 185.  1
1998 Högl BE, Gómez-Arévalo G, García S, Scipioni O, Rubio M, Blanco M, Gershanik OS. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology. 50: 1332-9. PMID 9595983  1
1998 Dziewczapolski G, Menalled LB, García MC, Mora MA, Gershanik OS, Rubinstein M. Opposite roles of D1 and D5 dopamine receptors in locomotion revealed by selective antisense oligonucleotides. Neuroreport. 9: 1-5. PMID 9592037  1
1998 Murer MG, Dziewczapolski G, Menalled LB, García MC, Agid Y, Gershanik O, Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Annals of Neurology. 43: 561-75. PMID 9585350 DOI: 10.1002/ana.410430504  1
1998 Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. 55: 23-30. PMID 9483167 DOI: 10.2165/00003495-199855001-00004  1
1997 Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski G, Zhang G, Fang Y, Larson JL, McDougall JA, Chester JA, Saez C, Pugsley TA, Gershanik O, Low MJ, Grandy DK. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell. 90: 991-1001. PMID 9323127 DOI: 10.1016/S0092-8674(00)80365-7  1
1997 Salin P, Dziewczapolski G, Gershanik OS, Nieoullon A, Raisman-Vozari R. Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat. Brain Research. Molecular Brain Research. 47: 311-21. PMID 9221930 DOI: 10.1016/S0169-328X(97)00068-5  1
1997 Gomez Arevalo G, Jorge R, Garcia S, Scipioni O, Gershanik O. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 12: 277-84. PMID 9159719 DOI: 10.1002/mds.870120303  1
1997 Dziewczapolski G, Murer G, Agid Y, Gershanik O, Raisman-Vozari R. Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats. Neuroreport. 8: 975-9. PMID 9141075  1
1997 Dziewczapolski G, Menalled LB, Savino MT, Mora M, Stefano FJ, Gershanik O. Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the "super-off" phenomenon. Movement Disorders : Official Journal of the Movement Disorder Society. 12: 159-66. PMID 9087973 DOI: 10.1002/mds.870120205  1
1997 Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology. 48: 363-8. PMID 9040722  1
1997 Block G, Liss C, Reines S, Irr J, Nibbelink D, Aarli J, Aguilar M, Ahrens S, Bakheit A, Baumel B, Bertoni J, Capildeo R, Castro-Caldas A, Deza L, Donaldson I, ... ... Gershanik O, et al. Comparison of immediate-release and controlled release Carbidopa/Levodopa in Parkinson's disease. A multicenter 5-year study European Neurology. 37: 23-27. PMID 9018028  1
1997 Dziewczapolski G, Mora MA, Menalled LB, Stéfano FJ, Rubinstein M, Gershanik OS. Threshold of dopamine content and D1 receptor stimulation necessary for the expression of rotational behavior induced by D2 receptor stimulation under normo and supersensitive conditions. Naunyn-Schmiedeberg's Archives of Pharmacology. 355: 30-5. PMID 9007839 DOI: 10.1007/PL00004914  1
1995 Micheli F, Gatto M, Gershanik O, Steinschnaider A, Fernandez Pardal M, Massaro M. Gilles de la Tourette syndrome: clinical features of 75 cases from Argentina. Behavioural Neurology. 8: 75-80. PMID 24487424 DOI: 10.3233/BEN-1995-8202  1
1995 Cammarota A, Gershanik OS, García S, Lera G. Cervical dystonia due to spinal cord ependymoma: involvement of cervical cord segments in the pathogenesis of dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 10: 500-3. PMID 7565833 DOI: 10.1002/mds.870100416  1
1994 Gershanik OS. Drug-induced parkinsonism in the aged. Recognition and prevention. Drugs & Aging. 5: 127-32. PMID 7981484 DOI: 10.2165/00002512-199405020-00006  1
1993 Arevalo GJ, Gershanik OS. Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 349-54. PMID 8341300 DOI: 10.1002/mds.870080317  1
1993 Gershanik OS. Drug-induced movement disorders. Current Opinion in Neurology and Neurosurgery. 6: 369-76. PMID 8099509  1
1992 Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Movement Disorders : Official Journal of the Movement Disorder Society. 7: 117-24. PMID 1350058 DOI: 10.1002/mds.870070204  1
1990 Gershanik OS, Nygaard TG. Parkinson's disease beginning before age 40. Advances in Neurology. 53: 251-8. PMID 2173370  1
1990 Rubinstein M, Muschietti JP, Gershanik O, Flawia MM, Stefano FJ. Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. The Journal of Pharmacology and Experimental Therapeutics. 252: 810-6. PMID 2138223  0.52
1989 Rubinstein M, Schinder AF, Gershanik O, Stefano FJ. Positive interaction between alpha-1 adrenergic and dopamine-2 receptors in locomotor activity of normo and supersensitive mice. Life Sciences. 44: 337-46. PMID 2536881 DOI: 10.1016/0024-3205(89)90227-0  1
1989 Gershanik OS, Rubinstein M, Stefano F. Inhibitory action of L-dopa. Neurology. 39: 1137. PMID 2527340  1
1988 Rubinstein M, Gershanik O, Stefano FJ. Postsynaptic bimodal effect of sulpiride on locomotor activity induced by pergolide in catecholamine-depleted mice. Naunyn-Schmiedeberg's Archives of Pharmacology. 337: 115-7. PMID 3368011 DOI: 10.1007/BF00169487  1
1988 Papa SM, Gershanik OS. Orthostatic tremor: an essential tremor variant? Movement Disorders : Official Journal of the Movement Disorder Society. 3: 97-108. PMID 3221905 DOI: 10.1002/mds.870030201  1
1988 Gershanik OS, Luquin MR, Scipioni O, Obeso JA. Isoniazid therapy in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 3: 133-9. PMID 3221901 DOI: 10.1002/mds.870030205  1
1988 Gershanik OS, Scipioni O, García S. Lisuride infusion pump in Parkinson's disease. A report of two cases. Journal of Neural Transmission. Supplementum. 27: 85-90. PMID 2969955  1
1988 Rubinstein M, Gershanik O, Stefano FJ. Different roles of D-1 and D-2 dopamine receptors involved in locomotor activity of supersensitive mice. European Journal of Pharmacology. 148: 419-26. PMID 2968273 DOI: 10.1016/0014-2999(88)90121-5  1
1987 Gershanik OS, Leist A. Juvenile onset Parkinson's disease. Advances in Neurology. 45: 213-6. PMID 3825691  1
1987 Starkstein S, Leiguarda R, Gershanik O, Berthier M. Neuropsychological disturbances in hemiparkinson's disease. Neurology. 37: 1762-4. PMID 3670613  1
1983 Gershanik O, Heikkila RE, Duvoisin RC. Effects of dopamine depletion on rotational behavior to dopamine agonists. Brain Research. 261: 358-60. PMID 6831221 DOI: 10.1016/0006-8993(83)90645-5  1
1983 Gershanik O, Heikkila RE, Duvoisin RC. Behavioral correlations of dopamine receptor activation. Neurology. 33: 1489-92. PMID 6605497  1
1982 Gershanik OS, Leist A. The role of bromocriptine in the management of Parkinson's disease | EL ROL DE LA BROMOCRIPTINA EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON Prensa Medica Argentina. 69: 725-730.  1
1982 Gershanik OS, Heikkila RE, Duvoisin RC, Manzino L. Behavioral correlates of dopamine receptor interaction Neurology. 32: A 161.  1
1979 Gershanik OS, Heikkila RE, Duvoisin RC. Asymmetric action of intraventricular monoamine neurotoxins. Brain Research. 174: 345-50. PMID 487133 DOI: 10.1016/0006-8993(79)90860-6  1
1979 Gershanik OS, Heikkila RE, Duvoisin RC. The role of serotonin neurons in the action of L-dopa in an animal model of parkinsonism Neurology. 29: 553.  1
1976 Thomson AF, Gershanik OS, Lahitou RE. Longterm treatment of parkinsonism with levodopa plus carbidopa | NUESTRA EXPERIENCIA EN EL TRATAMIENTO PROLONGADO DE LOS PARKINSONISMOS CON LA ASOCIACION L DOPO ALFAMETILDOPA HIDRAZINA Revista Neurologica Argentina. 2: 290.  1
1976 Thomson AF, Gershanik OS, Lahitou E. Long term treatment of parkinsonism with L-dopa and alpha methyldopa hydrazine. Our experience | NUESTRA EXPERIENCA EN EL TRATAMIENTO PROLONGADO DE LOS PARKINSONISMOS CON LA ASOCIACION L-DOPA-ALFAMETILDOPA HIDRAZINA Revista Neurologica Argentina. 2: 343-349.  1
Show low-probability matches.